described in section 319E(a)(4)(A) of the Public 
Health Service Act (42 U.S.C. 247d–5(a)(4)(A)). 
SEC. 5. ANTIMICROBIAL RESISTANCE CLINICAL RESEARCH 
AND PUBLIC HEALTH NETWORK. 
(a) IN GENERAL.—The Secretary, through the Direc-
tors of the Centers for Disease Control and Prevention 
and the National Institutes of Health, shall establish at 
least 10 Antimicrobial Resistance Clinical Research and 
Public Health Network sites to strengthen the national ca-
pacity to do the following: 
(1) Describe and confirm regional outbreaks 
through surveillance of locally available clinical 
specimens. 
(2) Rapidly assess, integrate, and address local 
and national antimicrobial resistance patterns. 
(3) Facilitate research concerning prevention, 
control, and treatment of resistant organisms. 
(4) Serve as a clinical trials network for opti-
mizing antimicrobial effectiveness. 
(b) GEOGRAPHIC DISTRIBUTION.—The sites estab-
lished under subsection (a) shall be geographically distrib-
uted across the United States, based in academic centers, 
health departments, and existing surveillance sites. 
(c) RESPONSIBILITIES.—The persons employed at 
the sites established under subsection (a) shall— 
VerDate Aug 31 2005 
23:01 Sep 28, 2007
Jkt 059200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H3697.IH
H3697
rwilkins on PROD1PC63 with BILLS
(1) monitor the emergence and changes in the 
patterns of antimicrobial resistant pathogens in peo-
ple; 
(2) study the molecular epidemiology of these 
pathogens; 
(3) evaluate the efficacy of new and existing 
interventions to prevent or limit the emergence of 
antimicrobial resistance throughout the geographic 
region of the site; 
(4) provide to the Centers for Disease Control 
and Prevention isolates of resistant pathogens, and 
in particular, pathogens that show new or atypical 
patterns of resistance adversely affecting public 
health; 
(5) conduct clinical research to develop natural 
histories of infectious disease and to study duration 
of antimicrobial use related to resistance develop-
ment, among other things; and 
(6) conduct basic antimicrobial resistance-re-
lated research. 
(d) COORDINATION.—These sites established under 
subsection (a) shall be authorized to share data and co-
operate with the Centers for Disease Control and Preven-
tion and the National Institutes of Health. 
VerDate Aug 31 2005 
23:01 Sep 28, 2007
Jkt 059200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6201
E:\BILLS\H3697.IH
H3697
rwilkins on PROD1PC63 with BILLS
(e) DATA ACCESS.—The Directors of the Centers for 
Disease Control and Prevention and the National Insti-
tutes of Health shall ensure that summary reports of data 
obtained by the Antimicrobial Resistance Clinical Re-
search and Public Health Network sites are made acces-
sible to the Antimicrobial Task Force for review on an 
ongoing basis. 
SEC. 6. ANTIMICROBIAL RESISTANCE QUALITY MEASURES 
DEMONSTRATION PROJECTS. 
Under section 319E(e) of the Public Health Service 
Act (42 U.S.C. 247d–5(e)), the Secretary of Health and 
Human Services, acting through the Director of the Office 
of Antimicrobial Resistance, shall award competitive 
grants to eligible entities to establish demonstration 
projects to assess the scope of the antimicrobial resistance 
problem and the level of appropriate and inappropriate use 
of antimicrobial drugs especially related to acute bacterial 
otitis media and upper respiratory infections, and in par-
ticular acute exacerbation of chronic bronchitis. One goal 
of the demonstration projects shall be the validation of 
models that may lead to the development of quality meas-
ures for health care providers prescribing antimicrobials. 
These demonstration programs shall be developed and im-
plemented through the direction of the Centers for Disease 
VerDate Aug 31 2005 
23:01 Sep 28, 2007
Jkt 059200
PO 00000
Frm 00031
Fmt 6652
Sfmt 6201
E:\BILLS\H3697.IH
H3697
rwilkins on PROD1PC63 with BILLS
Control and Prevention educational programs dedicated to 
the reduction of inappropriate antimicrobial use. 
SEC. 7. GAO REPORT. 
Not later than January 1, 2012, the Comptroller 
General of the United States shall submit a report to the 
Committee on Health, Education, Labor, and Pensions of 
the Senate and the Committee on Energy and Commerce 
of the House of Representatives that examines whether 
and how this Act has affected the ability to monitor, pre-
vent the spread of, and otherwise limit the impact of anti-
microbial resistance on human health. The report shall in-
clude any recommendations of the Comptroller General for 
modifying this Act. 
Æ 
VerDate Aug 31 2005 
23:01 Sep 28, 2007
Jkt 059200
PO 00000
Frm 00032
Fmt 6652
Sfmt 6301
E:\BILLS\H3697.IH
H3697
rwilkins on PROD1PC63 with BILLS